Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Refuses To File Translarna NDA; PTC Plummets

This article was originally published in Scrip

Executive Summary

Just as things looked like they couldn't get any worse for the Duchenne muscular dystrophy (DMD) research and development community – and for patients – PTC Therapeutics Inc. revealed it had received a refuse-to-file (RTF) letter from the FDA for the firm's new drug application (NDA) for Translarna (ataluren).

Advertisement

Related Content

PTC Tumbles On Ataluren Failure In Cystic Fibrosis
DMD Pipeline: After Sarepta’s First-Ever Approval, Are Combinations Next?
Sarepta Must Balance Exondys 51 Confirmatory Trials And Sales
Santhera Setback Could Have Wide-Reaching Effects For DMD Drugs
Marathon Looking To Go The Distance In DMD

Topics

Advertisement
UsernamePublicRestriction

Register

SC064575

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel